Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.

Twenty patients with acute myeloid leukaemia (AML) were treated with a combination of chemotherapy which included daunorubicin, cytosine arabino-side and 6-thioguanine (DAT). The complete remission rate was 85% and was achieved, in responsive cases, after an average of 2 courses of therapy. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Rees, J. K., Sandler, R. M., Challener, J., Hayhoe, F. G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1977
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025567/
https://www.ncbi.nlm.nih.gov/pubmed/271512
_version_ 1782136790262480896
author Rees, J. K.
Sandler, R. M.
Challener, J.
Hayhoe, F. G.
author_facet Rees, J. K.
Sandler, R. M.
Challener, J.
Hayhoe, F. G.
author_sort Rees, J. K.
collection PubMed
description Twenty patients with acute myeloid leukaemia (AML) were treated with a combination of chemotherapy which included daunorubicin, cytosine arabino-side and 6-thioguanine (DAT). The complete remission rate was 85% and was achieved, in responsive cases, after an average of 2 courses of therapy. Patients remained in hospital for an average of 37.5 days during remission-induction therapy and 3.7 days per month thereafter. The median remission period was 48 weeks and median survival was 70 weeks. A disappointing feature was the high relapse rate. This feature of the results re-affirms the need for a more effective form of remission therapy.
format Text
id pubmed-2025567
institution National Center for Biotechnology Information
language English
publishDate 1977
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20255672009-09-10 Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT. Rees, J. K. Sandler, R. M. Challener, J. Hayhoe, F. G. Br J Cancer Research Article Twenty patients with acute myeloid leukaemia (AML) were treated with a combination of chemotherapy which included daunorubicin, cytosine arabino-side and 6-thioguanine (DAT). The complete remission rate was 85% and was achieved, in responsive cases, after an average of 2 courses of therapy. Patients remained in hospital for an average of 37.5 days during remission-induction therapy and 3.7 days per month thereafter. The median remission period was 48 weeks and median survival was 70 weeks. A disappointing feature was the high relapse rate. This feature of the results re-affirms the need for a more effective form of remission therapy. Nature Publishing Group 1977-12 /pmc/articles/PMC2025567/ /pubmed/271512 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Rees, J. K.
Sandler, R. M.
Challener, J.
Hayhoe, F. G.
Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.
title Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.
title_full Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.
title_fullStr Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.
title_full_unstemmed Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.
title_short Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.
title_sort treatment of acute myeloid leukaemia with a triple cytotoxic regime: dat.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025567/
https://www.ncbi.nlm.nih.gov/pubmed/271512
work_keys_str_mv AT reesjk treatmentofacutemyeloidleukaemiawithatriplecytotoxicregimedat
AT sandlerrm treatmentofacutemyeloidleukaemiawithatriplecytotoxicregimedat
AT challenerj treatmentofacutemyeloidleukaemiawithatriplecytotoxicregimedat
AT hayhoefg treatmentofacutemyeloidleukaemiawithatriplecytotoxicregimedat

Ejemplares similares